drugset / Trial / NCT07274787
Safety And Effectiveness Of NaviFUS System With Bevacizumab In Recurrent Glioblastoma
NaSingle-groupOpen-labelTreatment
Summary
This study will evaluate the safety and early effectiveness of the NaviFUS system with concomitant microbubble administration in conjunction with BEV in recurrent GBM patients.
Timeline
- Start
- 2026-12-01
- Primary completion
- 2028-12-01
- Completion
- 2029-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | — | — |
| Background | Lumason | Diagnostic / imaging agent | — | Intravenous |